文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

2021-22季节性流感疫苗有效性中期估计——美国,2022年2月

Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-03-11

美国CDC利用2021年10月4日至2022年2月12日美国流感疫苗有效性网络中3636名急性呼吸道感染儿童和成人数据,估计2021-22季流感疫苗对实验室确诊、门诊就诊的A(H3N2)相关急性呼吸道感染的有效性为16%(95%CI=-16%至39%),认为无统计学显著性。分析表明流感疫苗接种未降低本季迄今占优势的A(H3N2)病毒所致门诊就诊风险。

要点

  • 本季流感疫苗对门诊A(H3N2)相关急性呼吸道感染的有效性为16%(95%CI=-16%至39%),无统计学显著性。
  • 登记病例数不足以按年龄组或疫苗产品类型生成可靠的有效性估计。
  • CDC建议医务人员在流感病毒流行期间继续为≥6月龄者接种流感疫苗,即使对某一病毒的有效性降低。

核心结论

  • 本分析表明流感疫苗接种未降低本季迄今占优势的A(H3N2)病毒所致门诊就诊风险。
  • 总体疫苗有效性为16%(95%CI=-16%至39%),被认为无统计学显著性。

研究设计与样本

  • 使用2021年10月4日至2022年2月12日美国流感疫苗有效性网络中3636名急性呼吸道感染儿童和成人的数据。
  • CDC自2004-05季以来每季估计季节性流感疫苗预防实验室确诊、轻/中度(门诊)就医急性呼吸道感染的有效性,2020-21季数据不足以生成估计。

主要发现

  • 2021-22季检测到的大多数流感病毒为A(H3N2)。
  • 总体疫苗有效性对A(H3N2)相关门诊就医急性呼吸道感染为16%(95%CI=-16%至39%),无统计学显著性。
  • 登记病例数不足以按年龄组或疫苗产品类型生成可靠的有效性估计。

关键数值与推荐

  • 美国建议所有≥6月龄者每年接种季节性流感疫苗,除非有禁忌证。
  • 目前可用的流感疫苗设计用于预防四种流感病毒:A(H1N1)pdm09(2009年大流行病毒)、A(H3N2)、B/Victoria系和B/Yamagata系。

临床怎么用

  • CDC建议流感抗病毒药物作为疫苗接种的辅助手段;在流感疫苗有效性降低的背景下,抗病毒药物的潜在公共卫生益处被放大。
  • CDC常规建议医务人员在流感病毒流行期间继续为≥6月龄者接种流感疫苗,即使对某一病毒的有效性降低,因为疫苗可预防A(H3N2)病毒感染相关的严重结局(如住院、重症监护室(ICU)入住或死亡),并可能预防本季后期可能流行的其他流感病毒。

局限性

  • 登记病例数不足以按年龄组或疫苗产品类型生成可靠的有效性估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months except when contraindicated (1). Currently available influenza vaccines are designed to protect against four influenza viruses: A(H1N1)pdm09 (the 2009 pandemic virus), A(H3N2), B/Victoria lineage, and B/Yamagata lineage. Most influenza viruses detected this season have been A(H3N2) (2). With the exception of the 2020-21 season, when data were insufficient to generate an estimate, CDC has estimated the effectiveness of seasonal influenza vaccine at preventing laboratory-confirmed, mild/moderate (outpatient) medically attended acute respiratory infection (ARI) each season since 2004-05. This interim report uses data from 3,636 children and adults with ARI enrolled in the U.S. Influenza Vaccine Effectiveness Network during October 4, 2021-February 12, 2022. Overall, vaccine effectiveness (VE) against medically attended outpatient ARI associated with influenza A(H3N2) virus was 16% (95% CI = -16% to 39%), which is considered not statistically significant. This analysis indicates that influenza vaccination did not reduce the risk for outpatient medically attended illness with influenza A(H3N2) viruses that predominated so far this season. Enrollment was insufficient to generate reliable VE estimates by age group or by type of influenza vaccine product (1). CDC recommends influenza antiviral medications as an adjunct to vaccination; the potential public health benefit of antiviral medications is magnified in the context of reduced influenza VE. CDC routinely recommends that health care providers continue to administer influenza vaccine to persons aged ≥6 months as long as influenza viruses are circulating, even when VE against one virus is reduced, because vaccine can prevent serious outcomes (e.g., hospitalization, intensive care unit (ICU) admission, or death) that are associated with influenza A(H3N2) virus infection and might protect against other influenza viruses that could circulate later in the season.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Chung JR, Kim SS, Kondor RJ, et al. Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35271561. doi:10.15585/mmwr.mm7110a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。